Pro-healing drug-eluting stents: A role for antioxidants?

Clinical Science

Volumn 114, Issue 3-4, 2008, Pages 265-273

  Watt, Jonathan ^a   Wadsworth, Roger ^a   Kennedy, Simon ^b   Oldroyd, Keith G ^c  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antioxidant; Drug eluting stent; Oxidative stress; Re endothelialization; Restenosis; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; BIOLIMUS; CANDESARTAN; CARVEDILOL; CILOSTAZOL; CLOPIDOGREL; EVEROLIMUS; MULTIVITAMIN; NADPH OXIDASE INHIBITOR; PACLITAXEL; PIMECROLIMUS; POLYMER; PROBUCOL; PROBUCOL SUCCINATE; RAPAMYCIN; SUPEROXIDE DISMUTASE; TACROLIMUS; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ANGIOPLASTY; ARTERY INTIMA PROLIFERATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; DRUG SAFETY; ENDOTHELIUM; FOLLOW UP; GENE THERAPY; HEALING; HEART INFARCTION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REGENERATION; RESTENOSIS; REVIEW; THROMBOSIS; GRAFT OCCLUSION; INJURY; PATHOLOGY; VASCULAR SMOOTH MUSCLE; WOUND HEALING;

ANTIOXIDANTS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; MUSCLE, SMOOTH, VASCULAR; WOUND HEALING;

EID: 38949168973     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070207     Document Type: Review

References (90)

1. Hoffmann, R. and Mintz, G. S. (2000) Coronary in-stent restenosis-predictors, treatment and prevention. Eur. Heart J. 21, 1739-1749
2. Welt, F. G. P. and Rogers, C. (2002) Inflammation and Restenosis in the Stent Era. Arterioscler. Thromb. Vasc. Biol. 22, 1769-1776
3. Moreno, P. R., Palacios, I. F., Leon, M. N., Rhodes, J., Fuster, V. and Fallon, J. T. (1999) Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am. J. Cardiol. 84, 462-466
4. Coomber, B. L. and Gotlieb, A. I. (1990) In vitro endothelial wound repair. Interaction of cell migration and proliferation. Arteriosclerosis 10, 215-222
5. Peiro, C., Redondo, J., Rodriguez-Martinez, M. A., Angulo, J., Marin, J. and Sanchez-Ferrer, C. F. (1995) Influence of Endothelium on Cultured Vascular Smooth Muscle Cell Proliferation. Hypertension 25, 748-751
6. Scott-Burden, T. and Vanhoutte, P. M. (1993) The endothelium as a regulator of vascular smooth muscle cell proliferation. Circulation 87, V51-V55
7. Werner, N., Junk, S., Laufs, U. et al. (2003) Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res. 93, 17e-24e
8. Aoki, J., Serruys, P. W., van Beusekom, H. et al. (2005) Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J. Am. Coll. Cardiol. 45, 1574-1579
9. Asahara, T., Chen, D., Tsurumi, Y. et al. (1996) Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 94, 3291-3302
10. Dulak, J., Schwarzacher, S. P., Zwick, R. H. et al. (2005) Effects of local gene transfer of VEGF on neointima formation after balloon injury in hypercholesterolemic rabbits. Vasc. Med. 10, 285-291
11. Hedman, M., Hartikainen, J., Syvanne, M. et al. (2003) Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107, 2677-2683
12. Walter, D. H., Cejna, M., Diaz-Sandoval, L. et al. (2004) Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110, 36-45
13. Loscalzo, J. (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 88, 756-762
14. De La Cruz, J. P., Moreno, A., Guerrero, A. and de La Cuesta, F. S. (2001) Antiplatelet effects of prostacyclin and nitric oxide in patients with type I diabetes and ischemic or edematous retinopathy. Platelets 12, 210-217
15. Marcus, A., Broekman, M., Drosopoulos, J. et al. (2001) Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler. Thromb. Vasc. Biol. 21, 178-182
16. Rosenberg, R. D. and Aird, W. C. (1999) Vascular-bed-specific hemostasis and hypercoagulable states. N. Engl. J. Med. 340, 1555-1564
17. Oliver, J. J., Webb, D. J. and Newby, D. E. (2005) Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler. Thromb. Vasc. Biol. 25, 2470-2479
18. Babapulle, M. N., Joseph, L., Belisle, P., Brophy, J. M. and Eisenberg, M. J. (2004) A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364, 583-591
19. Suzuki, T., Kopia, G., Hayashi, S. i. et al. (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104, 1188-1193
20. Zhou, X., Li, J. and Kucik, D. F. (2001) The microtubule cytoskeleton participates in control of β2 integrin avidity. J. Biol. Chem. 276, 44762-44769
21. Parry, T. J., Brosius, R., Thyagarajan, R. et al. (2005) Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur. J. Pharmacol. 524, 19-29
22. Butzal, M., Loges, S., Schweizer, M. et al. (2004) Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp. Cell Res. 300, 65-71
23. Joner, M., Finn, A. V., Farb, A. et al. (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193-202
24. Luscher, T. F., Steffel, J., Eberli, F. R. et al. (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115, 1051-1058
25. Takano, M., Ohba, T., Inami, S., Seimiya, K., Sakai, S. and Mizuno, K. (2006) Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur. Heart J. 27, 2189-2195
26. Kotani, J. i., Awata, M., Nanto, S. et al. (2006) Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J. Am. Coll. Cardiol. 47, 2108-2111
27. Oyabu, J., Ueda, Y., Ogasawara, N., Okada, K., Hirayama, A. and Kodama, K. (2006) Angioscopic evaluation of neointima coverage: sirolimus drug-eluting stent versus bare metal stent. Am. Heart J. 152, 1168-1174
28. Hong, M. K., Mintz, G. S., Lee, C. W. et al. (2006) Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 113, 414-419
29. Uren, N. G., Schwarzacher, S. P., Metz, J. A. et al. (2002) Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur. Heart J. 23, 124-132
30. Hofma, S. H., van der Giessen, W. J., van Dalen, B. M. et al. (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27, 166-170
31. Moreno, R., Fernandez, C., Hernandez, R. et al. (2005) Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J. Am. Coll. Cardiol. 45, 954-959
32. Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T. et al. (2006) Late clinical events after Clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48, 2584-2591
33. Nordmann, A. J., Briel, M. and Bucher, H. C. (2006) Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur. Heart J. 27, 2784-2814
34. Stone, G. W., Moses, J. W., Ellis, S. G. et al. (2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356, 998-1008
35. Fajadet, J., Wijns, W., Laarman, G. J. et al. (2006) Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114, 798-806
36. Kandzari, D. E., Leon, M. B., Popma, J. J. et al. (2006) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. 48, 2440-2447
37. Tsuchida, K., Piek, J. J., Neumann, F. J. et al. (2005) One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointervention 1, 266-272
38. Stone, G. W. (2007) SPIRIT HI results, American College of Cardiology Scientific Sessions, 24 March 2007, New Orleans
39. Grube, E., Sonoda, S., Ikeno, F. et al. (2004) Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109, 2168-2171
40. Tsuchiya, Y., Lansky, A. J., Costa, R. A. et al. (2006) Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am. J. Cardiol. 98, 464-469
41. Chevalier, B., Serruys, P. W., Silber, S. et al. (2007) Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. Eurointervention 2, 426-434
42. Vaina, S. and Serruys, P. W. (2006) Progressive stent technologies: new approaches for the treatment of cardiovascular diseases. Expert Opin. Drug Deliv. 3, 783-797
43. Mehilli, J., Kastrati, A., Wessely, R. et al. (2006) Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113, 273-279
44. Swanson, N., De Scheerder, I. K., Chevalier, B., Camenzind, E., Carver, A. and Gershlick, A. (2007) Two-year clinical results of a polymer-free, paclitaxel-eluting stent: the ELUTES trial. Eurointervention 3, 109-112
45. Morice, M. C., Bestehorn, H. P., Carrie, D. et al. (2006) Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomised JUPITER II trial. Eurointervention 2, 45-52
46. Lafont, A. (2007) Bioresorbable stents: the next horizon after drug eluting stents? Eurointervention 3, 21-23
47. Finn, A. V., Nakazawa, G., Joner, M. and Virmani, R. (2006) Everolimus eluting stents: beyond targeting restenosis! Eurointervention 2, 277-279
48. Mohacsi, P. J., Tuller, D., Hulliger, B. and Wijngaard, P. L. (1997) Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J. Heart Lung Transplant. 16, 484-492
49. Steffel, J., Latini, R. A., Akhmedov, A. et al. (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112, 2002-2011
50. Daemen, J., Wenaweser, P., Tsuchida, K. et al. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369, 667-678
51. Souza, H. P., Souza, L. C., Anastacio, V. M. et al. (2000) Vascular oxidant stress early after balloon injury: evidence for increased NAD(P)H oxidoreductase activity. Free Radical Biol. Med. 28, 1232-1242
52. Shi, Y., Niculescu, R., Wang, D., Patel, S., Davenpeck, K. L. and Zalewski, A. (2001) Increased NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. Arterioscler. Thromb. Vasc. Biol. 21, 739-745
53. Iuliano, L., Pratico, D., Greco, C. et al. (2001) Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J. Am. Coll. Cardiol. 37, 76-80
54. Azevedo, L. C., Pedro, M. A., Souza, L. C. et al. (2000) Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc. Res. 47, 436-445
55. Janiszewski, M., Pasqualucci, C. A., Souza, L. C., Pileggi, F., da Luz, P. L. and Laurindo, M. (1998) Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through a redox active metal-dependent pathway. Cardiovasc. Res. 39, 327-338
56. Landry, D. B., Couper, L. L., Bryant, S. R. and Lindner, V. (1997) Activation of the NF-κB and IκB system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am. J. Pathol. 151, 1085-1095
57. Ohtani, K., Egashira, K., Nakano, K. et al. (2006) Stent-based local delivery of nuclear factor-κB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation 114, 2773-2779
58. Griendling, K. K., Sorescu, D., Lassegue, B. and Ushio-Fukai, M. (2000) Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 20, 2175-2183
59. 2 for platelet-derived growth factor signal transduction. Science 270, 296-299
60. Nishi, K., Itabe, H., Uno, M. et al. (2002) Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler. Thromb. Vasc. Biol. 22, 1649-1654
61. Tsimikas, S., Lau, H. K., Han, K. R. et al. (2004) Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109, 3164-3170
62. Imanishi, T., Hano, T., Sawamura, T. and Nishio, I. (2004) Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction. Clin. Exp. Pharmacol. Physiol. 31, 407-413
63. Fujii, H., Li, S. H., Szmitko, P. E., Fedak, P. W. M. and Verma, S. (2006) C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 26, 2476-2482
64. van Aalst, J. A., Zhang, D. M., Miyazaki, K., Colles, S. M., Fox, P. L. and Graham, L. M. (2004) Role of reactive oxygen species in inhibition of endothelial cell migration by oxidized low-density lipoprotein. J. Vasc. Surg. 40, 1208-1215
65. van Aalst, J. A., Burmeister, W., Fox, P. L. and Graham, L. M. (2004) α-Tocopherol preserves endothelial cell migration in the presence of cell-oxidized low-density lipoprotein by inhibiting changes in cell membrane fluidity. J. Vasc. Surg. 39, 229-237
66. Kuzuya, M., Naito, M., Funaki, C. et al. (1991) Antioxidants stimulate endothelial cell proliferation in culture. Artery 18, 115-124
67. Kuzuya, M., Naito, M., Funaki, C., Hayashi, T., Asai, K. and Kuzuya, F. (1991) Probucol prevents oxidative injury to endothelial cells. J. Lipid Res. 32, 197-204
68. Noiri, E., Hu, Y., Bahou, W. F., Keese, C. R., Giaever, I. and Goligorsky, M. S. (1997) Permissive role of nitric oxide in cndothelin-induced migration of endothelial cells. J. Biol. Chem. 272, 1747-1752
69. Poppa, V., Miyashiro, J. K., Corson, M. A. and Berk, B. C. (1998) Endothelial NO synthase is increased in regenerating endothelium after denuding injury of the rat Aorta. Arterioscler. Thromb. Vasc. Biol. 18, 1312-1321
70. Pryor, W. A. and Squadrito, G. L. (1995) The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol. Lung Cell Mol. Physiol. 268, L699-L722
71. Zou, M. H., Cohen, R. and Ullrich, V. (2004) Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 11, 89-97
72. Jacobson, G. M., Dourron, H. M., Liu, J. et al. (2003) Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ. Res. 92, 637-643
73. Dourron, H. M., Jacobson, G. M., Park, J. L. et al. (2005) Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am. J. Physiol. Heart Circ. Physiol. 288, H946-H953
74. Laukkanen, M. O., Kivela, A., Rissanen, T. et al. (2002) Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 106, 1999-2003
75. Durand, E., Al Haj, Z. A., Addad, F. et al. (2005) Adenovirus-mediated gene transfer of superoxide dismutase and catalase decreases restenosis after balloon angioplasty. J. Vasc. Res. 42, 255-265
76. Six, I., Van Belle, E., Bordet, R. et al. (1999) L-Arginine and L-NAME have no effects on the reendothelialization process after arterial balloon injury. Cardiovasc. Res. 43, 731-738
77. Schneider, J. E., Berk, B. C., Gravanis, M. B. et al. (1993) Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation 88, 628-637
78. Miyauchi, K., Aikawa, M., Tani, T. et al. (1998) Effect of probucol on smooth muscle cell proliferation and dedifferentiation after vascular injury in rabbits: possible role of PDGF. Cardiovasc. Drugs Ther. 12, 251-260
79. Lau, A. K., Leichtweis, S. B., Hume, P. et al. (2003) Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation 107, 2031-2036
80. Deng, Y. M., Wu, B. J., Witting, P. K. and Stocker, R. (2004) Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 110, 1855-1860
81. Tardif, J. C., Cote, G., Lesperance, J. et al. (1997) Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. 337, 365-372
82. Yokoi, H., Daida, H., Kuwabara, Y. et al. (1997) Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J. Am. Coll. Cardiol. 30, 855-862
83. Cote, G., Tardif, J. C., Lesperance, J. et al. (1999) Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 99, 30-35
84. Sekiya, M., Funada, J., Watanabe, K., Miyagawa, M. and Akutsu, H. (1998) Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am. J. Cardiol. 82, 144-147
85. Kim, M. H., Cha, K. S., Han, J. Y., Kim, H. J. and Kim, J. S. (2002) Effect of antioxidant probucol for preventing stent restenosis. Catheter Cardiovasc. Interv. 57, 424-428
86. Wakeyama, T., Ogawa, H., Iida, H. et al. (2003) Effects of candesartan and probucol on restenosis after coronary stenting: results of insight of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ. J 67, 519-524
87. Tardif, J. C., Gregoire, J., Schwartz, L. et al. (2003) Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 107, 552-558
88. Nunes, G. L., Abizaid, A. C., Theodore, M. P. et al. (2006) Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. Am. Heart J. 152, 914-917
89. Tanous, D., Brasen, J. H., Choy, K. et al. (2006) Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re- endothelialization. Atherosclerosis 189, 342-349
90. Kim, W., Jeong, M. H., Cha, K. S. et al. (2005) Effect of anti-oxidant (Carvedilol and probucol) loaded stents in a porcine coronary restenosis model. Circ. J. 69, 101-106